Acute myelogenous leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development. Most AML subtypes are distinguished from other related blood disorders by the presence of more tha
Imaging tests Leukemia is a blood cancer that doesn't form solid tumors in your body. So, imaging tests such as X-rays, CT scans, MRIs, and ultrasounds won't help your doctor diagnose the cancer. But they can help your doctor figure out if you're having other problems, such as swell...
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. In AML, the bone marrow makes abnormal red blood cells, platelets, or myeloblasts (a type of immature white blood cell). These abnormal cells are called “blasts” and are the leukemia cells. These cells ...
[2]JosephDKhoury,EricSolary,Oussama Abla,etal.The5theditionof the World HealthOrganizationClassificationof HaematolymphoidTumours:Myeloidand Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1707-1708. [3]Kelemen, K. The Role of Nucleophosmi...
In an OncLive Peer Exchange® panel, experts discussed novel cytotoxic and targeted agents in the pipeline that are likely to provide new options for treating certain individuals with acute myeloid leukemia.
Novel immunotherapy for several tumors of the blood such as acute myelogenous leukemia (AML)The present invention relates to peptides, nucleic acids, and cells for use in immunotherapy. In particular, the present invention relates to cancer immunotherapy. The present invention further relates to a ...
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several genes are recurrently mutated, leading to new genomic classifications, predictive biomarkers, and new therapeutic targets. Mutations of the FMS-like tyrosine kinase 3 (
Acute myeloid leukemia (AML) is a heterogeneous disease with dismal response warranting the need for enhancing our understanding of AML biology. One prognostic feature associated with inferior response is the presence of activating mutations in FMS-like tyrosine kinase 3 (FLT3) especially occurrence of...
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was availab
2 · Sebastian Sager1 Received: 8 June 2023 / Accepted: 4 July 2023 / Published online: 3 August 2023 © The Author(s) 2023 Abstract Purpose Infections due to severe neutropenia are the most common therapy-associated causes of mortality in patients with acute myeloid leukemia (AML)...